A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$44.82-0.37 (-0.82%)
NVS$53.13-0.16 (-0.3%)
SNY$37.67-0.01 (-0.03%)
GSK$41.530.06 (0.14%)
click here
Conference Coverage
ASCO 2005 - Summary Coverage
Date: May 13-17, 2005
Location: Orlando, FL

The content presented here was prepared by independent authors under the editorial supervision of OncoEd and is not endorsed or sanctioned by the 41st Annual Meeting of the American Society of Clinical Oncology.
ASCO 2005
Date: May 13-17, 2005
Location: Orlando, FL
Author:

What Is New in Myelodysplastic Syndrome?

Adjuvant Therapy for Resectable Colon Cancer: Where Are We Now?

Pediatric Highlights from the 2005 American Society of Clinical Oncology Meeting

Update on Advanced Colorectal Cancer

Advances in the Management of Early Stage Breast Cancer

Anti-Angiogenic Therapy for Advanced Non-Small Cell Lung Cancer

Novel Targeted Agents Under Investigation for NSCLC

Targeting the EGFR Pathway in NSCLC

Update on the Use of Hematopoietic Growth Factors and Anemia: ASCO 2005

New Data Related to Monoclonal Antibody Therapy for Breast Cancer



Newsletters
Register in our member center today to receive a monthly newsletter with conference coverage updates.
Learn More »
Practice Resources
Learn how to have our conference coverage on your website.
Learn More »
Related News Stories
Two Studies Show Zevalin® Effective in Elderly Patients with Relapsed Lymphoma (6/30/2005)

Zevalin® Effective in Patients with Non-Hodgkin’s Lymphoma Who Have Failed Autologous Transplant (6/27/2005)

Velcade® Moderately Active in Non-Small Cell Lung Cancer (6/16/2005)

Tarceva® Improves Quality of Life in Refractory NSCLC (6/16/2005)

ProMune™ Immunotherapy Promising for Non-Small Cell Lung Cancer (6/16/2005)

Adjuvant Femara® Superior to Nolvadex® for Hormone Responsive Breast Cancer (6/15/2005)

Zometa® Reduces Bone Loss from Adjuvant Femara® In Early Breast Cancer (6/15/2005)

Oncotype DX™ Recurrence Score Predicts Outcome in Untreated and Tamoxifen Treated Breast Cancer (6/14/2005)

Large Study Validates Predictive Value of Oncotype DX™ for Breast Cancer Outcomes in Community Setting (6/13/2005)

Herceptin® for Adjuvant Therapy of HER2-Positive Breast Cancer Now Standard of Care (6/13/2005)

Statin Use Associated with Decreased Incidence of Prostate, Lung and Breast Cancer (5/31/2005)

Results Indicate Improved Long-term Survival with Addition of Herceptin® to Taxotere® in Metastatic Breast Cancer (5/31/2005)




© 1998-2007 CancerConsultants.com  All Rights Reserved.